Founded in 2005, Porton Pharma Solutions Ltd. is an internationally recognized pharmaceutical contract development and manufacturing organization (CDMO) in enabling our global clients to optimize drug development and manufacturing. We provide customer development and manufacturing services for Small Molecules, TIDES, Biologics, ADCs from pre-clinical to commercial. As of September 30, 2023, we have a proven record for the delivery of more than 2700 projects and established cooperation with more than 800 global clients. With our 5000+ skilled employees working across 20+ sites around the globe, Porton is committed to becoming the most open, innovative and reliable pharmaceutical service platform in the world and enabling the public's early access to good medicines. Porton is publicly listed on the Shenzhen Stock Exchange (Ticker: 300363).
2700+
Milestone Projects
800+
Global Customers
5
FDA/EMA/WHO/PMDA/ NMPA Inspections
80+
EHS Audits
400+
Quality Audits
Porton Founded
Established Porton USA & Europe (Sales), Shanghai (R&D)
Started CMO (Changshou) with R&D (Chongqing & Chengdu)
Listed on Shenzhen Stock Exchange
1st USFDA Inspection with Zero 483
Acquired J-Star Research Inc. (USA)
Past EMA Inspection, Started DP CDMO Services
Started DP Commercial Plant Operation; Acquired Fengxian (Shanghai) GMP Plant
Acquired Hubei Plant (China)